# Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead.

*business · news · 2026-04-09 · Seeking Alpha*

## Key points

- Low-cost semaglutide copies are now widely available in India's obesity drug market.
- These generics are eroding Eli Lilly's early market lead in India.
- Novo Nordisk faces its first significant competition in India from these cheaper alternatives.
- The availability of generics is rapidly transforming India's obesity treatment landscape.

**Companies:** Novo Nordisk A/S, Eli Lilly & Co.
**Countries:** India

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4573590-cheap-semaglutide-copies-in-india-challenge-novo-nordisk-cut-eli-lillys-lead-report)

---

Canonical: https://newsio.io/n/0f07c353-bfe5-49ab-a868-03e66b6925f4/cheap-semaglutide-copies-in-india-challenge-novo-nordisk-cut-eli-lillys-lead
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works